Kintor Pharmaceutical completes patient enrollment in KX-826 phase 2 trial
Kintor Pharmaceutical said that it has wrapped up patient enrollment for the phase 2 clinical trial of KX-826 (pyrilutamide) in China for the treatment of acne vulgaris. The Chinese biotech company has enrolled a total of 160 patients for the mid-stage clinical trial. According to Kintor Pharmaceutical, the randomized, double-blind, placebo-controlled clinical study to be […]